Resultados de investigación

Derecho Para Tod@s 1x02 En la segunda entrega de este programa especializado en derecho, conducido por la profesora de la UAL María del Mar Gómez junto a las alumnas Nuria Martínez y Olga Belmonte, el tema central son las compras online. Además, en la sección de "Nuestros expertos", las acompañan las responsables de la comisión de derecho animal del Colegio de Abogados de Almería y en "Juristas noveles", conocemos a Ainhora Sánchez.

Derecho Para Tod@s 1x01 Un espacio dedicado al Derecho, con secciones de actualidad, entrevistas a expertos, contacto con noveles juristas, repaso a la cultura y un rincón para hablar de la igualdad de género en materia legislativa. En este programa se analiza el Derecho animal

Primer programa de la segunda temporada del espacio Derecho Para Tod@s UAL, que coordina la profesora de la UAL María del Mar Gómez. En este espacio colaboran de forma habitual Nuria Martínez y Olga Belmonte. El tema central en el podcast ha sido la Innovación. Además, en la sección "Nuestros Expertos", el profesor Víctor Bastante nos habla de la gamificación en la enseñanza del Derecho, una práctica de innovación docente.

Derecho Para Tod@s 1x03 Programa realizado por María del Mar Gómez, Nuria Martínez y Olga Belmonte. Invitada Mª Ángeles Vila. En el programa de hoy se analiza la legislación en torno a la alimentación.

Programa realizado por María del Mar Gómez, Nuria Martínez y Olga Belmonte. Invitado hoy: Miguel Luque.

Derecho para tod@s - UAL es un Boletín jurídico mensual, cuyo objetivo es divulgar temas jurídicos que puedan ser de interés para la comunidad universitaria y contribuir a la formación integral de los estudiantes de la UAL.

To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain. Double-blind Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES) conducted in France, Germany, Poland and Spain evaluating treatment with CS+GH versus celecoxib in 606 patients with Kellgren and Lawrence grades 2-3 knee osteoarthritis and moderate-to-severe pain (Western Ontario and McMaster osteoarthritis index (WOMAC) score ≥301; 0-500 scale). Patients were randomised to receive 400 mg CS plus 500 mg GH three times a day or 200 mg celecoxib every day for 6 months. The primary outcome was the mean decrease in WOMAC pain from baseline to 6 months. Secondary outcomes included WOMAC function and stiffness, visual analogue scale for pain, presence of joint swelling/effusion, rescue medication consumption, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria and EuroQoL-5D. The adjusted mean change (95% CI) in WOMAC pain was -185.7 (-200.3 to -171.1) (50.1% decrease) with CS+GH and -186.8 (-201.7 to -171.9) (50.2% decrease) with celecoxib, meeting the non-inferiority margin of -40: -1.11 (-22.0 to 19.8; p=0.92). All sensitivity analyses were consistent with that result. At 6 months, 79.7% of patients in the combination group and 79.2% in the celecoxib group fulfilled OMERACT-OARSI criteria. Both groups elicited a reduction >50% in the presence of joint swelling; a similar reduction was seen for effusion. No differences were observed for the other secondary outcomes. Adverse events were low and similarly distributed between groups. CS+GH has comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile. NCT01425853., Si

Familial chylomicronemia syndrome (FCS) is a rare metabolic disorder caused by mutations in lipoprotein lipase (LPL) or genes required for LPL functionality and is characterized by hyperchylomicronemia that results in recurrent episodes of acute pancreatitis. Owing to the rarity of FCS, there are few case series describing the phenotypic variability in FCS patients in detail. To provide baseline characteristics in the largest study population to date of patients with FCS. We analyzed baseline demographic and clinical characteristics of adult FCS patients in the phase 3 APPROACH study of volanesorsen sodium (antisense inhibitor of apolipoprotein C-III). Sixty-six patients were included in the analysis. Mean (SD) age was 46 (13) years; and mean body mass index was 24.9 (5.7) kg/m2. We identified causal mutations in 79% (52) of patients, with LPL mutations accounting for 62% (41) of cases. Median age at diagnosis was 24 years, 54% were females, and 81% were Caucasian. All patients followed a low-fat diet, 43% received fibrates, 27% fish oils, and 21% statins. Median fasting triglyceride levels (P25, P75) were 1985 (1179, 3047 mg/dL). Overall, 76% of patients reported ≥1 lifetime episode of acute pancreatitis; 23 patients reported a total of 53 pancreatitis events in the 5 years before enrollment. Our data emphasize the severe hypertriglyceridemia characteristic of FCS patients despite restrictive low-fat diets and frequent use of existing hypolipemic therapies. Acute pancreatitis and recurrent acute pancreatitis are frequent complications of FCS. Diagnosis at an older age suggests likely underdiagnosis and underappreciation of this rare disorder., Si

Despite considerable advances in our understanding of the pathophysiology of graft-versus-host disease (GVHD), its prediction remains unresolved and depends mainly on clinical data. The aim of this study is to build a predictive model based on clinical variables and cytokine gene polymorphism for predicting acute GVHD (aGVHD) and chronic GVHD (cGVHD) from the analysis of a large cohort of HLA-identical sibling donor allogeneic stem cell transplant (allo-SCT) patients. A total of 25 SNPs in 12 cytokine genes were evaluated in 509 patients. Data were analyzed using a linear regression model and the least absolute shrinkage and selection operator (LASSO). The statistical model was constructed by randomly selecting 85% of cases (training set), and the predictive ability was confirmed based on the remaining 15% of cases (test set). Models including clinical and genetic variables (CG-M) predicted severe aGVHD significantly better than models including only clinical variables (C-M) or only genetic variables (G-M). For grades 3-4 aGVHD, the correct classification rates (CCR1) were: 100% for CG-M, 88% for G-M, and 50% for C-M. On the other hand, CG-M and G-M predicted extensive cGVHD better than C-M (CCR1: 80% vs. 66.7%, respectively). A risk score was calculated based on LASSO multivariate analyses. It was able to correctly stratify patients who developed grades 3-4 aGVHD (P < .001) and extensive cGVHD (P < .001). The novel predictive models proposed here improve the prediction of severe GVHD after allo-SCT. This approach could facilitate personalized risk-adapted clinical management of patients undergoing allo-SCT., The authors would like to thank the Centro Nacional de Genotipado for help with genotyping. They would also like to acknowledge the patients who participated in this study, as well as the staff of the Hematology Department, Hospital General Universitario Gregorio Marañón (Madrid, Spain), who made the study possible. This study was partially supported by Ministry of Economy and Competitiveness ISCIII-FIS Grants PI08/1463, PI11/00708, PI14/01731, PI17/01880, and RD12/0036/0061 and cofinanced by the European Regional Development Fund from the European Commission, the “A way of making Europe” initiative, and grants from Fundación LAIR and Asociación Madrileña de Hematología y Hemoterapia, Si

La viñeta se difundía a través de la página web del programa CARNE CRUDA y del espacio dedicado al autor Juan Gallego en eldiario.es y que, hoy en día, es la manera de acceder a todas y cada una de las viñetas realizadas: https://www.eldiario.es/autores/juan_gallego/, El documento recoge el trabajo desarrollado como humorista gráfico llevado a cabo para el programa CARNE CRUDA y editado a través de ELDIARIO.ES consistente en un total de 225 viñetas de humor gráfico relacionadas con la actualidad social española. El periodo en el que se desarrolló comprende entre el 3 de Septiembre de 2015 y el 29 de junio de 2017